Finvest
QGEN Life sciences tools · Diagnostics · Consumables · Molecular testing · Thesis updated July 18, 2026

Recurring kits carry a slower instrument cycle

01 Running thesis

Consumables are doing the heavy lifting

Qiagen’s best trait is that most of its sales repeat. Labs buy its kits, reagents, and related products again and again after they adopt a workflow. Management said these recurring revenues are about 90% of total sales, which helps protect the business when customers delay big equipment buys.

That mix is showing up in margins. Adjusted operating margin reached 29.5% in 2025, up 80 basis points from 2024, even though tariffs and currency were a drag. QuantiFERON for latent tuberculosis and QIAstat-Dx for syndromic testing remain important growth engines.

The bear case is not broken, though. Instrument demand is still weak because labs are careful with capital spending. QIAGEN Digital Insights is moving more pharma customers to SaaS subscriptions, which can hold back near-term reported revenue before the subscription base matures.

The next year is mostly about execution. Investors need to watch who becomes the next CEO, whether 2028 margin goals stay realistic, and whether the new sample prep systems launch on time in late 2026.

Feb 2026▲Qiagen closed 2025 with adjusted operating margin of 29.5%, up 80 basis points despite tariff pressure. The Parse Biosciences deal was completed in December 2025, and the $500 million share repurchase finished in January 2026.
Nov 2025→The thesis added a clear CEO transition risk after Thierry Bernard said he would step down. At the same time, Qiagen raised EPS guidance, announced Parse Biosciences, and moved ahead with a $500 million synthetic share repurchase.
May 2025▲Q1 2025 reinforced the value of Qiagen’s roughly 90% recurring revenue mix. Management also moved toward more shareholder returns with a proposed annual cash dividend and a new buyback authorization.
Feb 2025→Qiagen ended 2024 with strong margin performance and double-digit growth from QuantiFERON and QIAstat-Dx. Instrument recovery was pushed out, and tariff uncertainty became a clearer risk.
Nov 2024▲Q3 2024 showed margin expansion and regulatory progress for QIAstat and QIAcuity. The update also added the near-term revenue drag from moving QIAGEN Digital Insights customers to SaaS.
Aug 2024→Q2 2024 showed that consumables could offset a sharp decline in instruments. Qiagen also chose to phase out NeuMoDx and focus resources on stronger areas.
02 Business model

Razors, blades, and lab software

Qiagen follows a razor and blade model. The instrument is the razor. The test kits, sample prep products, reagents, and related consumables are the blades. That is why the company can still earn good margins when instrument sales are soft.

The company also sells bioinformatics through QIAGEN Digital Insights. Bioinformatics means software that helps scientists read and use biology data. QDI is moving pharma customers from longer license deals to SaaS, which means software sold as a subscription.

Qiagen sits in the middle of precision medicine. Drug companies, research labs, hospitals, and liquid biopsy developers use its tools to prepare samples, detect disease markers, and turn raw biology into usable answers.

Capital return is part of the story. Qiagen completed a $500 million share repurchase in January 2026 and has recently added an annual cash dividend. That helps shareholders, but it does not remove the need for steady organic growth.

03 Product portfolio

The products Finn watches

Growth engine

QuantiFERON

QuantiFERON is Qiagen’s latent tuberculosis testing franchise. The company is also working on a fifth generation assay, which could refresh the product line if it performs well.

Growth engine

QIAstat-Dx

QIAstat-Dx is used for syndromic testing, which checks for many possible causes of illness in one run. Its menu has expanded, including Gastrointestinal Panel Mini B and V in the U.S.

Option

QIAcuity

QIAcuity is Qiagen’s digital PCR platform, a precise way to count DNA or RNA targets. The system expanded multiplexing from 5 to 12 targets per sample.

Steady

QIAGEN Digital Insights

QIAGEN Digital Insights sells bioinformatics tools to researchers and pharma customers. The move to SaaS can pressure near-term revenue, but it should make the business more recurring over time.

Cash cow

Sample technologies and automation

Sample prep is a core part of Qiagen’s Sample to Insight workflow. QIAsymphony Connect, QIAsprint Connect, and QIAmini are planned as new automated systems by the end of 2026.

Option

Parse Biosciences

Parse Biosciences extends Qiagen into single-cell analysis, a field that studies one cell at a time. The deal closed in December 2025 and adds a higher-growth bet to sample technologies.

04 Business segments

Mostly repeat-use products

Consumables and related revenue90%modest
Instruments10%declining

This mix reflects management’s 2025 commentary that recurring revenues are about 90% of sales. Instruments are the smaller piece and remain more exposed to cautious lab capital spending.

05 Risk factors

What could go wrong

Instrument freeze lasts longer

Medium impact · High odds

Qiagen’s consumables are steady, but weak instrument placements can slow future pull-through. If labs keep delaying capital purchases, the installed base may grow more slowly than planned.

We watchInstrument sales growth and management comments on lab capital spending.

CEO handoff disrupts execution

High impact · Medium odds

Thierry Bernard’s planned exit adds risk at an important time. A new CEO will have to protect margin gains, finish the Parse integration, and keep the 2028 targets credible.

We watchNew CEO appointment, 2028 margin target updates, and any change in capital return policy.

Tariffs and currency pressure margins

Medium impact · Medium odds

Qiagen expanded margins in 2025 despite tariffs, but management has already flagged tariff and currency pressure. In Q3 2025, management cited more than 150 basis points of combined headwinds from currency movements and U.S. tariffs.

We watchAdjusted operating margin, tariff commentary, and gross margin bridge details.

China stays weak

Low impact · High odds

China is no longer a large part of the company, at about 3% to 4% of sales in Q1 2025. Still, a high-teens CER decline shows the market remains a drag and can hurt regional growth.

We watchChina CER growth and Asia Pacific revenue trends.

QDI SaaS shift masks demand

Medium impact · Medium odds

Moving QIAGEN Digital Insights customers to SaaS can reduce near-term reported revenue because subscription revenue is recognized over time. That is healthy if retention and bookings stay strong, but harmful if customers use the shift to leave or spend less.

We watchQDI revenue growth, subscription renewals, and pharma customer commentary.
06 Quick answers

In one breath

What does Qiagen do?

Qiagen makes tools that help labs move from a biological sample to a useful result. Its products include sample prep kits, molecular tests, diagnostic systems, digital PCR tools, and bioinformatics software.

Why does Qiagen have so much recurring revenue?

Many customers need to keep buying kits, reagents, and related consumables after they set up a Qiagen workflow. Management says these recurring revenues are about 90% of total sales.

What is the main bull case for QGEN stock?

The bull case is that recurring consumables keep growing and margins keep expanding. Parse Biosciences, QuantiFERON, QIAstat-Dx, and new automation systems could add growth if execution stays on track.

What is the main risk for Qiagen?

The biggest near-term risk is execution during a CEO transition while instrument spending remains weak. Tariffs, currency, China weakness, and the QDI SaaS shift add more pressure.